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Abstract
Background: The Steno hypothesis states that changes in basement membrane anionic charge
leads to diabetic microvascular complications. In diabetic nephropathy, loss of basement membrane
glycosaminoglycans and the association between glomerular basement membrane heparan sulphate
and proteinuria has been documented. A correlation between erythrocyte surface and the
glomerular capillary wall charges has also been observed.
The aim of this study is to evaluate the relationship between retinopathy and erythrocyte anionic
charge and urinary glycosaminoglycan excretion in type 2 diabetic patients.
Methods: 49 subjects (58 ± 7 yrs, M/F 27/22) with type 2 diabetes with proliferative retinopathy
(n = 13), nonproliferative retinopathy (n = 13) and without retinopathy (n = 23) were included in
the study. 38 healthy subjects were selected as control group (57 ± 5 yrs, M/F 19/19). Erythrocyte
anionic charge (EAC) was determined by the binding of the cationic dye, alcian blue. Urinary
glycosaminoglycan and microalbumin excretion were measured.
Results: EAC was significantly decreased in diabetic patients with retinopathy (255 ± 30 ng alcian
blue/106 RBC, 312 ± 30 ng alcian blue/106 RBC for diabetic and control groups respectively, p <
0.001). We did not observe an association between urinary GAG and microalbumin excretion and
diabetic retinopathy. EAC is found to be negatively corralated with microalbuminuria in all groups.
Conclusions: We conclude that type 2 diabetic patients with low erythrocyte anionic charge are
associated with diabetic retinopathy. Reduction of negative charge of basement membranes may
indicate general changes in microvasculature rather than retinopathy. More prospective and large
studies needs to clarify the role of glycosaminoglycans on progression of retinopathy in type 2
diabetic patients.
Background
Diabetic retinopathy is the leading cause of blindness in
diabetic adults [1,2]. During the first two decades of the
disease, nearly all patients with type 1 diabetes and > 60
% of type 2 diabetes have retinopathy. The duration of the
diabetes is probably the strongest predictor for
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development and progression of retinopathy [3]. The inci-
dence of retinopathy positively correlates with HbA1c [4].
Diabetic patients with evidence of nephropathy are char-
acterized by a 5 to 10 times higher incidence of prolifera-
tive retinopathy [5]. Albuminuria not only is associated
with kidney disease but, is also a strong predictor of cardi-
ovascular disease and proliferative retinopathy, suggesting
it reflects a generalized vascular disease [6]. Thus, the
coincidence of generalized vascular dysfunction, albu-
minuria, mesangial expansion, proliferative retinopathy
and accelerated development of atherosclerosis suggests a
common cause of abnormalities in susceptible diabetic
patients.
The Steno hypothesis proposed that increased loss of ani-
onic charge from basement membranes leads to diabetic
microangiopathy [7]. This hypothesis has been proven for
diabetic nephropathy but it's not clear for diabetic
retinopathy.
Anionic content of basement membranes predominantly
produced by glycosaminoglycan molecules (GAG). They
constitute the charge selective barrier of the glomerul
basement membrane [8]. Several clinical studies indicate
that loss of the GAG is associated with diabetic albuminu-
ria in diabetic and experimental models [9,10].
Although abnormal GAG metabolism is a well known
phenomen in diabetic nephropathy, it is still debated
whether it has a pathogenic role in diabetic retinopathy.
The aim of this study was to evaluate the relationship
between diabetic retinopathy and erythrocyte anionic
charge as well as the urinary glycosaminoglycan excretion
in type 2 diabetic patients.
Methods
49 outpatients (27 male, 22 female) with type 2 diabetes
mellitus diagnosed after the age of 30, were included and
divided into 3 subgroups according to severety of retinop-
athy. Diabetes was diagnosed according to American Dia-
betes Association criteria. The onset of diabetes was after
the age of 30 in these patients.
The study was approved by the institutional ethics com-
mittee and patients gave written informed consent. Exclu-
sion criteria included hypertension, myocardial
infarction, cerebrovascular disease, heart failure, treat-
ment with antiaggregants, steroids or other drugs that
effect blood pressure and glucose, serum creatinine > 200
µmol/l, connective tissue disorders and other systemic
disease.
Renal and bladder infection diseases of patients and con-
trols were excluded biochemically and microbiologically.
The ocular fundus was examined by an ophthalmologist
after dilation of the pupils and classified. The patients
were divided into three groups according to the severity of
retinopathy. Group 1 consisted of 23 patients without
retinopathy (R0). Group 2 consisted of 13 patients with
nonproliferative retinopathy (R1-hemorrhages, microan-
eurysms, cotton-wool exudates). The 13 patients in group
3 (R2) had proliferative retinopathy (R2-neovascularisa-
tions, vitreous hemorrhages, ablatio of the retina).
Age and sex matched 38 healthy volunteers were included
as healthy controls. Demographic characteristics of the
groups are shown in Table 1.
Venous samples were collected after an overnight fast and
24 hour urine samples collected.
The charge on erythrocytes (RBC) was measured by means
of cationic dye alcian blue 8GX (Sigma catalogue no: A
5268) according to the method of Levin with minor mod-
ifications as follows: [11]. From citrated venous blood
samples, platelets and leukocytes were removed using the
method of Beutler et al. [12]. After removal of platelets
and leucocytes erythrocytes were washed 3 times in phos-
phate buffered saline (PBS), and subsequently a fraction
of RBC was resuspended in PBS containing alcian blue at
a final concentration of 250 mg/l. After a 30 min incuba-
tion at 37°C, the RBC suspension was centrifuged, and
the remaining alcian blue concentration was measured in
the supernatant with a Shimadzu UV 1201 V spectropho-
tometer (Shimadzu, Japan) at a wavelength of 650 nm.
Each determination represents the mean of 2 assays. The
quantity of alcian blue bound to RBCs was expressed as
Table 1: Demographic characteristics of the study group
Control group Group R0 GroupR1 Group R2
A g e ( y r s ) 5 7  ±  55 9  ±  85 6  ±  55 7  ±  5
M/F 19/19 13/10 7/6 7/6
BMI(kg/m2 ) 28 ± 5 27.8 ± 6 29.6 ± 5 28.5 ± 8
OAD/insulin - 22/1 12/1 12/1
Duration of diabetes (yrs) - 10 ± 5 11 ± 6 12 ± 8BMC Ophthalmology 2004, 4:14 http://www.biomedcentral.com/1471-2415/4/14
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nanograms of alcian blue per 106 RBCs. In our experimen-
tal conditions the intraassay and interassay coefficients of
variation were 5.8 and 7.6 % for 100 nanograms of alcian
blue per 106 RBCs.
Urinary glycosaminoglycan (UGAG) excretion was deter-
mined in 24 hr urine samples spectrophotometrically at
520 nm by the addition of dimethylmethylene blue
(Aldrich Chem Co., USA) and bovine kidney heparan sul-
fate as standard (Sigma catalogue no H 7640) [13]. In our
experimental conditions the intraassay and interassay
coefficients of variation were 1.5 and 2.4 % for 10 mg/l
glycosaminoglycan, respectively.
Serum sialic acid was measured in serum with a colori-
metric method described by Svennerholm with a Shi-
madzu UV-1201 spectrophotometer (Shimadzu, Japan)
with a wavelength of 525 nm. Using N-acetyl neuraminic
acid (Sigma catalogue no: A 3007) as standard [14]. Intra
assay and interassay coefficients of variations were 6.6 and
9.2 % for 1 mmol/l sialic acid respectively.
Urinary albumin excretion was measured by an immuno-
turbidemetric assay (Roche diagnostics, USA) on auto-
mated clinical chemistry analyzer (Hitachi 902). In all
patients, the annual level was determined as the mean of
urinary albumin excretions in three 24 h urine collections
taken at home during normal physical activity. The
intraassay and interassay coefficients of variation were 1.3
and 4.3 % for a mean value of 25 mg/l albumin
concentration.
Serum glucose, cholesterol, triglyceride and HDL (Dade
Behring, USA) were evaluated with enzymatic methods
(Dade Behring, USA) on an automated clinical chemistry
analyzer (Dimension RxL). Creatinin was assayed by the
Jaffe reaction on an automated clinical chemistry analyzer
(Dimension RxL).
HbA1C (reference range 4.4–6.0 %) was measured by a tur-
bidimetric inhibition immunoassay technique (Roche
Diagnostics, USA) on automated clinical chemistry ana-
lyzer (Hitachi 902). The intraassay and interassay coeffi-
cients of variation were 1.8 and 3.0 % for a mean value of
10.5 % HbA1C concentration.
The analysis of the data was performed with a PC compat-
ible Instat-II programme. Paired t test and ANOVA were
used where appropriate. Correlation analysis was per-
formed with Spearman rank test. The differences were
considered significant when the probability was p < 0.05.
The results were given as mean ± SD.
Results
The clinical characteristics of the study groups are shown
in Table 1. There were no difference in age and BMI
between the groups. Duration of diabetes mellitus was
slightly longer, although not significantly different than
that of the patients with proliferative retinopathy.
Results of laboratory parameters are shown in Table 2.
Patients with proliferative retinopathy had higher concen-
trations of triglyceride and lower concentrations of HDL
cholesterol as compared to diabetics without evidence of
retinopathy and control group. Serum cholesterol level
was the same in all study groups. Blood glucose and
HbA1C levels were not different in subgroups of our dia-
betic population.
Distribution of erythrocyte anionic charges of all study
groups are demonstrated in figure 1. EAC was 312 ± 30 ng
alcian blue/106 RBC in healthy controls. Diabetic patients
both with nonproliferative and proliferative retinopathy
had a significantly lower alcian blue binding to RBCs
compared with diabetic patients without retinopathy (p <
0.001).
Table 2: Laboratory parameters of the study groups
Control group Group R0 GroupR1 Group R2
Fasting glucose (mg/dl) 100 ± 26 229 ± 70 234 ± 89 236 ± 120
HbA1c (%) 7.6 ± 0.7 8.0 ± 0.7 8.0 ± 0.8
Cholesterol (mg/dl) 192 ± 44 187 ± 33 197 ± 41 193 ± 40
Triglycerides (mg/dl) 131 ± 55 153 ± 84 199 ± 71 228 ± 143
HDL (mg/dl) 45 ± 9 39 ± 9 37 ± 7 36 ± 10
Serum sialic acid (mmol/l) 1.81 ± 0.3 2.0 ± 0.5 2.1 ± 0.3 2.3 ± 0.5
EAC (ng alcian blue 106 erythrocyte) 312 ± 30 281 ± 30 259 ± 23 252 ± 37
UGAG (mg/24 h) 5.0 ± 2.4 8.3 ± 4.1 8.7 ± 4.8 8.4 ± 3.3
Microalbumin (mg/24 h) 10 ± 6 73 ± 40 75 ± 21 85 ± 45BMC Ophthalmology 2004, 4:14 http://www.biomedcentral.com/1471-2415/4/14
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A marked (p < 0.05) difference was found between type 2
diabetic patients (8.3 ± 4.1, 8.7 ± 4.8, 8.4 ± 3.3 mg/24 h,
Table 2) and controls (5.0 ± 2.4 mg/24 h) regarding uri-
nary GAG excretion. We did not observe a correlation
between urinary GAG excretion and diabetic retinopathy.
A significant difference (p < 0.05) was observed in serum
sialic acid values in diabetic patients compared with
healthy controls. Serum sialic acid level was higher in the
nonproliferative retinopathy group, but the difference was
statistically insignificant (p > 0.05).
Microalbumin level was significantly p < 0.05 higher in
diabetic patients (73 ± 40 [35–250], 75 ± 21 [50–202], 85
± 45 [56–224] mg/24 h, Table 2) compared to healthy
controls (10 ± 6 mg/24 h). But there wasn't a correlation
between the severity of retinopathy and microalbuminu-
ria (p > 0.05).
Results of the Spearman rank correlation test are shown
on table 3. EAC is found to be negatively corralated with
microalbuminuria in all groups.
Discussion
Our study demonstrates a statistically significant quantita-
tive reduction of alcian blue binding to RBCs in diabetic
patients than healthy subjects, which is in accordance
with literature [15,16]. Previously we have shown a statis-
tically significant quantitative reduction of alcian blue
binding to RBCs in streptozosin diabetic rats [17]. Alcian
blue is a complex amphoteric molecule that binds to
acidic glycoproteins which represent a large class of cell
surface anionic molecules [18]. As alcian blue binding is
an expression of the anionic charge on the cell surface,
this result indicates that RBC anionic charge is reduced in
diabetic patients.
Erythrocyte anionic charge by itself is unlikely to be
important in the pathogenesis of diabetic retinopathy but
reduced RBC alcian blue binding was found to be associ-
ated with the loss of glomerular basement membrane ani-
onic charges in diabetic rats and patients [19]. Changes in
the composition of basement membranes are likely to be
responsible for functional disturbances and hence for the
development of capillary disease. Chakrabarti et al.
reported a decreased density of anionic sites in the retinal
basement membrane of BB rats [20]. A similar decrease in
anionic density was also demonstrated in the Bruch's
membrane of BB and streptozosin diabetic rats [21].
Several authors have questioned the validity of the alcian
blue binding assay. The major objections concern the
incomplete alcian blue dissolution in PBS buffer and its
tendency to precipitate with time [22,23]. We prepared a
fresh alcian blue solution for each experiment. Each
experiment was considered valid when no change in the
optical density of the blank alcian blue solution occurred
over the duration of the experiment. In addition, the
experiments were done in batches with cells from a
healthy person. Therefore any flaw in the methodology
would not affect only one group and thus distort the
results.
Diabetic retinopathy is characterized by gradually pro-
gressive alterations in the retinal microvasculature leading
to vascular hyperpermeability, capillary occlusion and
ultimately neovascularization. Thickening of the retinal
microvascular basement membrane and loss of anionic
content are well documented morphological features of
diabetic retinopathy [20,21,24]. These changes causes
breakdown of the blood-retinal barrier resulting in capil-
lary hyperpermeability and leakage of proteins into the
deep and superficial layers of the retina [1,2].
Distribution of erythrocyte anionic charges of all study  groups Figure 1
Distribution of erythrocyte anionic charges of all study 
groups.
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Table 3: Correlation analysis between erythrocyte anionic charge 
(EAC) and other parameters.
EAC (ng AB/ 106 erythrocyte)
rP
HbA1c (%) -0.251 0.073
Microalbumin (mg/24 h) -0.393 0.032*
UGAG (mg/24 h) -0.226 0.094
Serum sialic acid (mmol/L) 0.095 0.546
Duration of diabetes (yrs) 0.097 0.478
* Statistically significant at 0.05 level.BMC Ophthalmology 2004, 4:14 http://www.biomedcentral.com/1471-2415/4/14
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Glycosaminoglycan primarily heparan sulfate has been
implicated in permeability properties of basement mem-
brane of glomerular basement membrane as well as the
retinal basement membrane [25]. Kahaly et al. reported
that urinary GAG excretion is increased in diabetic
patients with microangiopathy [26]. Williamson et al and
Ginn et al. have shown that albumin permeation is
increased into the diabetic compared to normal retina
[27,28]. Loss of heparan sulfate from the retinal basement
membrane in addition to its thickening may cause
increased vascular permeation of albumin and other sub-
stances into the retina and possibly into the optic nerve.
Systemic treatment of IDDM patients with proteinuria
with danaparoid sodium, a glycosaminoglycan, not only
reduced proteinuria, but also decreased the number of
hard exudates in the retina [29]. Studies in diabetic rats
have shown reduced activity of the key enzyme in the bio-
synthesis of heparan sulfate, N-deacetylase, which results
in impaired heparan sulfate biosynthesis in experimental
diabetes [30,31].
In this study we found that urinary GAG excretion is
increased in diabetic patients than healthy controls, but
there was no difference in GAG excretion between non-
proliferative and proliferative retinopathy patients. We
couldn't find a correlation between GAG excretion and
EAC but we found a correlation between albumin excre-
tion and EAC. Although our working hypothesis is that
the reduction in anionic charge in basement membranes
may be due to an abnormal GAG metabolism, we
couldn't confirm it with this study.
Our study did not directly address the pathophysiology of
diabetic retinopathy but a reduction in erythrocyte charge
perhaps connected with the properties of retinal basement
membrane.
Several reports suggest that elevated serum sialic acid lev-
els in type 1 and type 2 diabetic patients indicate microv-
ascular damage [32,33]. In our study, diabetic patients
were found to have elevated serum sialic acid levels in
comparison with healthy controls. Therefore, the increase
in serum sialic acid level may indicate a coincidence
between the structural alterations in the retina and general
vascular damage.
Conclusions
We conclude that type 2 diabetic patients with low eryth-
rocyte anionic charge are associated with diabetic retinop-
athy. Reduction of negative charge of basement
membranes may indicate general changes in microvascu-
lature rather than retinopathy. More prospective and large
studies needs to clarify the role of glycosaminoglycans on
progression of retinopathy in type 2 diabetic patients.
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